I2I
TEVA icon

Insight 2811 Inc’s Teva Pharmaceuticals TEVA Stock Holding History

Insight 2811 Inc’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,428
Closed -$323K – 103
2016
Q2 		$323K Buy
6,428
+3
+0% +$160 0.12% 95
2016
Q1 		$344K Sell
6,425
-295
-4% -$17.3K 0.14% 90
2015
Q4 		$441K Hold
6,720
– – 0.21% 73
2015
Q3 		$379K Sell
6,720
-6,980
-51% -$453K 0.22% 79
2015
Q2 		$810K Sell
13,700
-152
-1% -$9.38K 0.39% 49
2015
Q1 		$863K Sell
13,852
-2,325
-14% -$135K 0.41% 45
2014
Q4 		$930K Sell
16,177
-360
-2% -$20.1K 0.45% 39
2014
Q3 		$889K Sell
16,537
-471
-3% -$25K 0.38% 45
2014
Q2 		$892K Sell
17,008
-1,073
-6% -$54.8K 0.37% 48
2014
Q1 		$955K Buy
18,081
+68
+0.4% +$3.14K 0.4% 41
2013
Q4 		$722K Sell
18,013
-2,350
-12% -$92.5K 0.36% 56
2013
Q3 		$769K Sell
20,363
-1,745
-8% -$68.1K 0.38% 56
2013
Q2 		$867K Buy
+22,108
New +$861K 0.48% 44

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Insight 2811 Inc's TEVA Position: Q3 2016 in Review

Insight 2811 Inc sold out of Teva Pharmaceuticals (TEVA) in Q3 2016, closing a stake of 6,428 shares — an estimated $323K sold.

Insight 2811 Inc first reported a position in TEVA in Q2 2013 and held it in 13 quarters. The position peaked at $955K in Q1 2014. 795 funds tracked by Wall St. Rank hold TEVA as of Q3 2016.

  • Insight 2811 Inc reported no remaining Teva Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Insight 2811 Inc sold 6,428 Teva Pharmaceuticals shares in Q3 2016, an estimated $323K.
  • Insight 2811 Inc first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Insight 2811 Inc's Teva Pharmaceuticals position peaked at $955K in Q1 2014.
  • 795 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2016.

Based on Insight 2811 Inc's 13F filing for Q3 2016, filed 25 Oct 2016.